“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

17 April 2019
Pharma

Visiongain has published a new pharma report Top 25 Biosimilar Drug Manufacturers : Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

There is an extensive pipeline for biosimilars at the moment, with the main targets being the best-selling biologics who have patent expiry’s coming up. This patent cliff will provide a lot of opportunities for biosimilars manufacturers to gain a larger market share and could see biosimilars being placed into the spotlight as a viable and logical way of diversifying a company’s pharmaceutical portfolio. This will also see more entrants to this market which could see it become more consolidated and competitive in the future.

This report profiled the selected companies: 3SBio, Amega Biotech, Beijing ShuangLu Pharmaceuticals, Biocad, Biocon, Biosidus, Bioton, Celltrion, Dong-A, Dr Reddy’s Laboratories, Intas Biopharmaceutical, LG Life Sciences and other companies.

The lead analyst commented that "The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature. Big pharma companies will enter the market and more companies will start to consolidate to avoid a hostile takeover and to protect their market position. Once more money is invested in researching biosimilars, progress will be made on the technology used, the type of biosimilars they can create and the cost of doing so.

Visiongain predicts the biosimilars landscape will change owing to the arrival of more big-name pharma companies into the biosimilars scene. With an ever-increasing market size, technological advancements and strong R&D pipelines, the biosimilars market is in a great position to continue its rise as one of the key new pharmaceutical sectors. That progress will highlight its ability to benefit companies, healthcare professionals and patients."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

Read

Visiongain Publishes Next Generation Sequencing Market Report 2021-2031

Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.

04 June 2021

Read

Visiongain Publishes Anti-infective Vaccines Market Report 2021-2031

The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.

04 June 2021

Read

Visiongain Publishes Anti-infective Agents Market Report 2021-2031

Rising incidences of infectious diseases is one of the prime factors driving the growth of the global anti-infective agents market globally.

27 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever